Smead Capital Management Inc. lessened its holdings in Amgen, Inc. (NASDAQ:AMGN) by 1.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 712,902 shares of the medical research company’s stock after selling 9,547 shares during the period. Amgen makes up 6.3% of Smead Capital Management Inc.’s investment portfolio, making the stock its 2nd largest position. Smead Capital Management Inc. owned 0.10% of Amgen worth $132,921,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in AMGN. FMR LLC lifted its stake in Amgen by 4.8% during the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. lifted its stake in Amgen by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after acquiring an additional 489,720 shares in the last quarter. BlackRock Inc. lifted its stake in Amgen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after acquiring an additional 909,689 shares in the last quarter. Nordea Investment Management AB lifted its stake in Amgen by 12.9% during the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Amgen by 3.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,968,892 shares of the medical research company’s stock worth $683,562,000 after acquiring an additional 121,202 shares in the last quarter. 78.59% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,575 shares of company stock valued at $1,508,836. Insiders own 0.19% of the company’s stock.
Amgen, Inc. (NASDAQ AMGN) traded down $12.26 on Monday, hitting $174.75. The stock had a trading volume of 6,728,035 shares, compared to its average volume of 3,020,000. The stock has a market cap of $126,850.00, a P/E ratio of 67.73, a P/E/G ratio of 2.69 and a beta of 1.42. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the company earned $2.89 earnings per share. analysts forecast that Amgen, Inc. will post 12.96 EPS for the current year.
Amgen announced that its board has authorized a share repurchase program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be given a $1.32 dividend. The ex-dividend date is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.02%. Amgen’s dividend payout ratio is 178.29%.
Several equities analysts recently issued reports on the company. Atlantic Securities lowered Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 target price on the stock. in a research note on Monday. Leerink Swann reissued a “market perform” rating on shares of Amgen in a research note on Friday. Royal Bank of Canada cut their price target on Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a report on Thursday, October 26th. Oppenheimer set a $205.00 price target on Amgen and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Sixteen analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Amgen currently has an average rating of “Hold” and a consensus price target of $191.49.
ILLEGAL ACTIVITY WARNING: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/05/amgen-inc-amgn-is-smead-capital-management-inc-s-2nd-largest-position.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.